Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.57 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9642398 | 0.93 | CALCRL (0.56) | CTSCCALCRLRENBACE1KMT2A | |
| SCHEMBL18568248 | 0.93 | CALCRL (0.56) | CTSCCALCRLRENBACE1KMT2A | |
| SCHEMBL8953885 | 0.93 | CALCRL (0.56) | CTSCCALCRLRENBACE1KMT2A | |
| SCHEMBL30123252 | 0.93 | CTSC (0.59) | CTSCCALCRLLMNATDP1REN | |
| SCHEMBL29433973 | 0.92 | CALCRL (0.56) | CTSCCALCRLRENBACE1 | |
| SCHEMBL30239995 | 0.92 | CTSC (0.52) | CTSCCALCRLLMNATDP1REN | |
| SCHEMBL30240006 | 0.92 | CTSC (0.48) | CTSCCALCRLBACE1MMEACE | |
| SCHEMBL30051852 | 0.91 | REN (0.58) | CTSCLMNATDP1RENMME | |
| SCHEMBL30051563 | 0.89 | CTSC (0.59) | CTSCCALCRLLMNATDP1REN | |
| SCHEMBL29695560 | 0.88 | CTSC (0.58) | CTSCCALCRLLMNATDP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250339504-A1 | CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS | NATIONAL CANCER CENTER (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20230151057-A1 | LACTIC ACID BACTERIA GROWTH PROMOTER | ASAHI GROUP HOLDINGS, LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4159742-A1 | LACTIC ACID BACTERIA GROWTH PROMOTER | Asahi Group Holdings, Ltd. (JP) | 2023-04-05 | — | — | EP | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885CALCRL 1193/4885LMNA 1538/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSC 37/4885CALCRL 219/4885LMNA 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.